144 ·Filed Jun 26, 2026

TYRA

Tyra Biosciences, Inc.
BEARISH
Impact 6/10
Horizondays Processed3mo ago SEC0001628280-26-045813
Form 144 — notice of proposed sale of securities
Actionable Insight ▼ Bearish

Monitor for execution of the 144 sale; continued distribution by this VC holder could pressure the stock near-term. TYRA's strong institutional support and 90% analyst buy rating provide a cushion, but the selling pattern warrants caution in the coming days to weeks.

DirectionBearish
Confidencemedium
Horizondays
Final — all horizons settled through T+60d
TYRA ▼ -20.37% at T+60d
SHORT call ✓ call won +20.37% · α vs SPY +24.75% · entry $32.11 → $25.57
Entry anchored
Jun 26, 03:59 PM ET
via exchange tick
T+1d
-0.53%
call +0.53% · α +1.31%
$31.94
settled 3mo ago
T+5d
-3.89%
call +3.89% · α +5.28%
$30.86
settled 3mo ago
T+20d
-4.61%
call +4.61% · α +4.33%
$30.63
settled 2mo ago
T+60d
-20.37%
call +20.37% · α +24.75%
$25.57
settled 10d ago

Price Chart

Loading chart...

Executive Summary

Nextech VI Oncology SCSP, a significant VC shareholder, filed a Form 144 to sell 308,379 shares (~$9.5M) after already selling ~129k shares (~$4M) in the prior week. This signals near-term profit-taking and creates overhang, potentially weighing on TYRA shares despite strong fundamentals.

Key Facts

  • Nextech VI Oncology SCSP plans to sell 308,379 common shares, valued at ~$9.5M.
  • Same entity sold 128,949 shares (~$4.0M) in the week prior (June 1, 23-25, 2026).
  • Proposed sale is ~0.58% of TYRA's $1.8B market cap; combined recent+proposed is ~0.75%.
  • Shares were acquired in a private placement on Sep 17, 2021, now being steadily sold.

Financial Impact

~$9.5M proposed sale, combined recent and proposed ~$13.6M

dilutionfloatsupply overhang

Risk Factors

  • Further selling by Nextech VI Oncology SCSP beyond the proposed 308k shares
  • Negative signal from a major early investor reducing its stake
  • Potential short-term price dislocation from large block sale

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (21 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001628280-26-045813
Document: 0001628280-26-045813-index.html0001628280-26-045813
Document: 0001628280-26-045813.txt0001628280-26-045813
9 reports for TYRA
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for TYRA — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
S-3ASR
NEUTRAL ★ 3/10
$25.07 $25.65▲ +2.31%▲ +2.21%$20.50 (−18.21%)
Sep 9, 2026
23d ago
8-K
BULLISH ★ 6/10
$22.01 $24.35▲ +10.63%▲ +11.73%$20.50 (−6.84%)
Aug 4, 2026
8w ago
424B5
BEARISH ★ 6/10
$25.71 $25.30▲ +1.59%▲ +1.95%$20.50 (+20.25%)
Jun 26, 2026
13w ago
144
BEARISH ★ 6/10
$32.11 $30.86▲ +3.89%▲ +5.28%$20.50 (+36.14%)
May 13, 2026
20w ago
8-K
MIXED ★ 5/10
$36.19 $33.78▼ −6.66%▼ −5.50%$20.50 (−43.34%)
Apr 20, 2026
23w ago
3
NEUTRAL ★ 2/10
$36.69 $35.06▼ −4.44%▼ −5.53%$20.50 (−44.11%)
Apr 17, 2026
24w ago
DEFA14A
NEUTRAL ★ 4/10
$35.56 $37.59▲ +5.71%▲ +5.15%$20.50 (−42.34%)
Apr 17, 2026
24w ago
8-K
NEUTRAL ★ 3/10
$35.56 $37.59▲ +5.71%▲ +5.15%$20.50 (−42.34%)
Apr 13, 2026
24w ago
144
NEUTRAL ★ 2/10
$35.27 $36.69▲ +4.03%▲ +2.63%$20.50 (−41.86%)
Showing 9 of 9

US Market Status

Market Open — Closes in 3h 55m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access